When non-small cell lung cancer (NSCLC) metastasizes to other parts of the body, it may spread to the brain. Whole brain radiation therapy is one way to treat these brain metastases, but they often continue to grow.
Veliparib (also called ABT-888) is an investigational drug being assessed for treating several types of cancer. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make whole brain radiation treatment work more effectively against brain metastases from NSCLC.
The purpose of this study is to evaluate the safety and effectiveness of whole brain radiation therapy with veliparib and with a placebo in patients with brain metastases from NSCLC. Patients will be randomly assigned to one of three groups: whole brain radiation plus low-dose veliparib, whole brain radiation plus high-dose veliparib, or whole brain radiation plus a placebo. Veliparib is a capsule that is taken orally (by mouth).